Syros Pharmaceuticals Inc... (SYRS)
NASDAQ: SYRS
· Real-Time Price · USD
0.03
0.00 (19.52%)
At close: Jun 09, 2025, 3:26 PM
Syros Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | 386K | 3.76M | 2.83M | 2.95M | -5.47M | 3.89M | 6.28M | 5.47M | 7.8M | 5.7M | 5.16M | 4.83M |
Cost of Revenue | 325K | 331K | 334K | 279K | 616K | 653K | 704K | 770K | 724K | 726K | 747K | n/a | n/a | n/a | n/a |
Gross Profit | -325K | -331K | -334K | 107K | 3.15M | 2.18M | 2.25M | -6.24M | 3.17M | 5.55M | 4.72M | 7.8M | 5.7M | 5.16M | 4.83M |
Operating Income | -26.18M | -27.42M | -30.92M | -27M | -34.64M | -34M | -33.21M | -36M | -39.45M | -33.77M | -26.65M | -25.42M | -26.91M | -26.14M | -20.94M |
Interest Income | 793K | 1.08M | 1.55M | 1.28M | 1.63M | 2.13M | 1.77M | 1.59M | 392K | 112K | 35K | 31K | 32K | 12K | 10K |
Pretax Income | -6.4M | -23.33M | -3.71M | -64.38M | -40.14M | -36.26M | -23.79M | -4.77M | -30.25M | -34.48M | -25.15M | -23.81M | -26.03M | -22.49M | -14.23M |
Net Income | -6.4M | -23.33M | -3.71M | -64.38M | -40.14M | -36.26M | -14.92M | 27.57M | -21.05M | -35.19M | -23.64M | -23.81M | -26.03M | -22.49M | -14.23M |
Selling & General & Admin | 5.66M | 5.46M | 6.27M | 5.89M | 7.76M | 7.22M | 7.41M | 7.33M | 8.08M | 6.95M | 6.95M | 6.43M | 5.35M | 5.52M | 5.74M |
Research & Development | 20.53M | 21.62M | 24.32M | 21.22M | 28.28M | 29.61M | 28.76M | 27.91M | 25.76M | 33.1M | 25.17M | 26.8M | 27.26M | 25.79M | 20.03M |
Other Expenses | n/a | -21.95M | n/a | 135K | 2.35M | n/a | n/a | 9.51M | -9.51M | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 26.18M | 27.09M | 30.59M | 27.11M | 38.4M | 36.83M | 36.17M | 35.24M | 33.84M | 40.05M | 32.12M | 33.23M | 32.61M | 31.31M | 25.77M |
Interest Expense | 1.31M | 1.38M | 1.31M | 1.33M | 1.3M | 1.28M | 1.22M | 1.13M | 1.05M | 981K | 976K | 986K | 984K | 969K | 967K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 26.18M | 27.42M | 30.92M | 27.39M | 38.4M | 36.83M | 36.17M | 35.24M | 33.84M | 40.05M | 32.12M | 33.23M | 32.61M | 31.31M | 25.77M |
Income Tax Expense | n/a | n/a | 290.72K | 10.88M | -3.3M | 1.28M | -8.87M | -32.35M | -9.2M | 712K | -1.51M | 986K | 984K | 969K | 967K |
Shares Outstanding (Basic) | 39.27M | 39.27M | 38.98M | 29.54M | 27.99M | 27.91M | 27.84M | 27.75M | 9.42M | 6.38M | 6.31M | 6.29M | 6.29M | 6.25M | 6.14M |
Shares Outstanding (Diluted) | 39.34M | 39.27M | 38.98M | 29.54M | 27.99M | 27.91M | 27.84M | 27.75M | 9.42M | 6.38M | 6.31M | 6.29M | 6.29M | 6.29M | 6.14M |
EPS (Basic) | -0.16 | -0.59 | -0.1 | -2.18 | -1.43 | -1.3 | -0.54 | 0.99 | -2.24 | -5.51 | -3.75 | -3.78 | -4.14 | -3.6 | -2.32 |
EPS (Diluted) | -0.16 | -0.59 | -0.1 | -2.18 | -1.43 | -1.3 | -0.54 | 0.99 | -2.24 | -5.51 | -3.75 | -3.78 | -4.14 | -3.58 | -2.32 |
EBITDA | -4.76M | -21.61M | -2.07M | -62.78M | -38.22M | -34.33M | -21.87M | -2.88M | -28.48M | -32.77M | -23.42M | -22.05M | -24.28M | -20.77M | -12.53M |
EBIT | -5.08M | -21.95M | -2.4M | -63.05M | -38.84M | -34.98M | -22.57M | -3.65M | -29.2M | -33.5M | -24.17M | -22.83M | -25.04M | -21.52M | -13.26M |
Depreciation & Amortization | 325K | 331K | 334K | 279K | 616K | 653K | 704K | 770K | 724K | 726K | 747K | 773K | 767K | 749K | 731K |